Cargando…

Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years

Historically, neoadjuvant chemotherapy (NACT) was extrapolated from adjuvant regimens. Dual HER2 blockade and the introduction of carboplatin for triple negative breast cancers (TNBC) emerged by December 2013 and have improved pathological complete response (pCR) rates. The objective of this study w...

Descripción completa

Detalles Bibliográficos
Autores principales:	McFarland, Daniel C., Naikan, Jessica, Rozenblit, Mariya, Mandeli, John, Bleiweiss, Ira, Tiersten, Amy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921638/ https://www.ncbi.nlm.nih.gov/pubmed/27382369 http://dx.doi.org/10.1155/2016/4324863

Ejemplares similares

A Unique Presentation of Occult Primary Breast Cancer with a Review of the Literature
por: Ahmed, Inaya, et al.
Publicado: (2015)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?
por: Savaridas, Sarah L., et al.
Publicado: (2019)

Assessing the Correlation of Rate of Pathological Complete Response and Outcome in Post Neoadjuvant Chemotherapy Setting and Molecular Subtypes of Breast Cancer
por: Omair, Ahmad, et al.
Publicado: (2023)

Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer
por: Dou, He, et al.
Publicado: (2023)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
por: Resende, Uanderson, et al.
Publicado: (2019)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alba, Emilio, et al.
Publicado: (2016)

Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer
por: Chen, Yong-He, et al.
Publicado: (2020)

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
por: Goorts, Briete, et al.
Publicado: (2017)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
por: Tanioka, M, et al.
Publicado: (2010)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer
por: Al-Tweigeri, Taher, et al.
Publicado: (2021)

Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report
por: Tang, Wen‐Fang, et al.
Publicado: (2021)

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
por: de Freitas, Ana Julia Aguiar, et al.
Publicado: (2021)

Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer
por: Ma, Sung Jun, et al.
Publicado: (2022)

Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response
por: Li, Xianjun, et al.
Publicado: (2020)

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Ocaña, Alberto, et al.
Publicado: (2022)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period
por: Choi, Misun, et al.
Publicado: (2017)

Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Kuerer, Henry M, et al.
Publicado: (2016)

Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer
por: Cuello-López, Javier, et al.
Publicado: (2018)

A pathological complete response after neoadjuvant triplet chemotherapy for locally advanced transverse colon cancer
por: Tominaga, Tetsuro, et al.
Publicado: (2020)

Complete pathological response of post neoadjuvant chemotherapy in colorectal cancer with liver metastasis: a case report
por: Al Jazzar, Ragad I, et al.
Publicado: (2022)

ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
por: de CASTRO, Juliana Silveira Lima, et al.
Publicado: (2021)

Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
por: Acevedo, Francisco, et al.
Publicado: (2022)

Radiomics of contrast-enhanced spectral mammography for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer
por: Zhang, Kun, et al.
Publicado: (2023)

Regional Arterial Infusion Chemotherapy improves the Pathological Response rate for advanced gastric cancer with Short-term Neoadjuvant Chemotherapy
por: Wu, Zhen-Feng, et al.
Publicado: (2015)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Neoadjuvant chemotherapy and pathologic response: a retrospective cohort
por: de Andrade, Diocésio Alves Pinto, et al.
Publicado: (2013)

Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy
por: Weiss, Anna, et al.
Publicado: (2018)

PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
por: Shi, Qiyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5seah9bq7d03jrstpr4pronlci